315 related articles for article (PubMed ID: 15929107)
21. Caring for patients with sickle cell disease in North Carolina.
Telen MJ; Harris G; Whitworth E
N C Med J; 1999; 60(1):14-7. PubMed ID: 9951281
[No Abstract] [Full Text] [Related]
22. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
Kratovil T; Bulas D; Driscoll MC; Speller-Brown B; McCarter R; Minniti CP
Pediatr Blood Cancer; 2006 Dec; 47(7):894-900. PubMed ID: 16526051
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
24. The measurement of urinary hydroxyurea in sickle cell anaemia.
Dalton RN; Turner C; Dick M; Height SE; Awogbade M; Inusa B; Okpala I; O'Driscoll S; Thein SL; Rees DC
Br J Haematol; 2005 Jul; 130(1):138-44. PubMed ID: 15982356
[TBL] [Abstract][Full Text] [Related]
25. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
Grigg A
Intern Med J; 2007 Mar; 37(3):190-2. PubMed ID: 17316339
[TBL] [Abstract][Full Text] [Related]
26. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease.
Oyeku SO; Driscoll MC; Cohen HW; Trachtman R; Pashankar F; Mullen C; Giardina PJ; Velazco N; Racine AD; Green NS
Pediatr Blood Cancer; 2013 Apr; 60(4):653-8. PubMed ID: 23129068
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
Rogers ZR
Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
[TBL] [Abstract][Full Text] [Related]
28. Improving Uptake of Hydroxyurea in Patients with Sickle Cell Disease: A Retrospective Study of a Clinic-based Change in Consenting Practices.
Smith AW; Bodas P; Sidebotham L; Weilnau J; Wildman B
J Natl Med Assoc; 2019 Apr; 111(2):169-175. PubMed ID: 30314826
[TBL] [Abstract][Full Text] [Related]
29. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
30. Hydroxyurea for children with sickle cell disease.
Heeney MM; Ware RE
Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
[TBL] [Abstract][Full Text] [Related]
31. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea.
Ballas SK; Marcolina MJ; Dover GJ; Barton FB
Br J Haematol; 1999 May; 105(2):491-6. PubMed ID: 10233426
[TBL] [Abstract][Full Text] [Related]
32. Understanding patient-related barriers to hydroxyurea use among adolescent and adult patients with sickle cell disease in Mulago and Kiruddu hospitals, Uganda, a qualitative study.
Namaganda P; Nantume P; Mubiru KR; Twimukye A; Wiltshire CS
BMC Health Serv Res; 2024 May; 24(1):666. PubMed ID: 38802815
[TBL] [Abstract][Full Text] [Related]
33. Sickle cell patients find a brand New World.
Noonan SS
N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
[TBL] [Abstract][Full Text] [Related]
34. Ten-year review of hospital admissions among children with sickle cell disease in Kuwait.
Akar NA; Adekile A
Med Princ Pract; 2008; 17(5):404-8. PubMed ID: 18685282
[TBL] [Abstract][Full Text] [Related]
35. Higher nocturnal and awake oxygen saturations in children with sickle cell disease receiving hydroxyurea therapy.
Narang I; Kadmon G; Lai D; Dhanju S; Kirby-Allen M; Odame I; Amin R; Lu Z; Al-Saleh S
Ann Am Thorac Soc; 2015 Jul; 12(7):1044-9. PubMed ID: 25970812
[TBL] [Abstract][Full Text] [Related]
36. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
[TBL] [Abstract][Full Text] [Related]
37. Haemoglobin F modulation in childhood sickle cell disease.
Trompeter S; Roberts I
Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic and genotoxic monitoring of sickle cell anaemia patients treated with hydroxyurea.
Khayat AS; Antunes LM; Guimarães AC; Bahia MO; Lemos JA; Cabral IR; Lima PD; Amorim MI; Cardoso PC; Smith MA; Santos RA; Burbano RR
Clin Exp Med; 2006 Mar; 6(1):33-7. PubMed ID: 16550342
[TBL] [Abstract][Full Text] [Related]
39. [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
Mellouli F; Bejaoui M
Arch Pediatr; 2008 Jan; 15(1):24-8. PubMed ID: 18164913
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
Nevin J; Myers L; Osunkwo I; Kanter J
J Pediatr Hematol Oncol; 2014 Apr; 36(3):e180-4. PubMed ID: 24072249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
